Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
XFOR Stock Chart & Stats
$4.07
-$0.07(-10.26%)
At close: 4:00 PM EST
$4.07
-$0.07(-10.26%)
Day’s Range― - ―
52-Week Range$1.35 - $9.30
Previous CloseN/A
Volume769.31K
Average Volume (3M)550.43K
Market Cap
$370.04M
Enterprise Value-$93.33M
Total Cash (Recent Filing)$253.00M
Total Debt (Recent Filing)$77.28M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Apr 30, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding90,919,690
10 Day Avg. Volume628,675
30 Day Avg. Volume550,428
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market Cap-0.25
Enterprise Value/Revenue-2.66
Enterprise Value/Gross Profit-3.23
Enterprise Value/Ebitda1.09
Forecast
1Y Price Target
$12.00Price Target Upside194.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$10.13M
Bulls Say, Bears Say
Bulls Say
Regulatory Approval ProgressA CHMP positive opinion materially de-risks EU commercialization for mavorixafor, potentially making it the first available therapy for WHIM syndrome in Europe. That structural regulatory progress raises the probability of a sustained revenue stream and supports long-term market access planning.
Strong Liquidity / RunwayA ~$253M cash position and multi-year runway materially reduces near-term financing risk and allows the company to fund pivotal trials and initial commercialization activities. This liquidity supports execution of strategic plans and provides time to reach revenue inflection points without urgent dilutive financing.
Revenue Step-Up And Gross MarginsA large revenue step-up and strong gross profit suggest early commercial traction or milestone-driven income that can scale. Durable higher top-line and healthy product-level margins improve the path to unit economics and indicate the business can generate meaningful revenue as approvals and launch activities proceed.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow implies the business still consumes significant capital to run trials and commercial activities. Over the medium term this raises funding dependency and execution risk if commercialization or trial timelines slip, despite the current runway.
Substantial Operating LossesLarge ongoing operating and net losses indicate the company remains far from break-even, limiting internal reinvestment capacity and pressuring equity economics. Persistent losses can constrain strategic flexibility and mean long-term value depends on successful commercialization or approval milestones.
Clinical-stage, Single-Asset ConcentrationDependence on a single lead product in clinical and early commercialization stages concentrates binary trial and regulatory risk. Even with EU progress, setbacks in pivotal trials, label scope, or launch execution could materially impair revenue prospects and growth durability over the medium term.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $1.35 and its highest was $9.30 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $370.04M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Apr 30, 2026 which is in 37 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Mar 17, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.272 by $0.052.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.2.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 90,919,690 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.272. Following the earnings report the stock price went up 18.82%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (194.84% Upside)
$12.00 (194.84% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.13%
12-Months-Change
Fundamentals
Return on Equity
-115.27%
Trailing 12-Months
Asset Growth
98.34%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
XFOR Stock 12 Month Forecast
Average Price Target
$12.00
▲(194.84% Upside)
Technical Analysis
Ownership Overview
1.06% Insiders
16.42% Mutual Funds
69.46% Other Institutional Investors
9.36% Public Companies and
Individual Investors